Response on Pneumococcal Vaccine in Preterm Infants After Neutral and Acidic Oligosaccharides Supplementation

Pediatr Infect Dis J. 2015 Sep;34(9):976-82. doi: 10.1097/INF.0000000000000766.

Abstract

Background: Supplementation of oligosaccharides in premature infants was shown to influence the immune system. We determined the effect of combined short-chain galacto-oligosaccharides (scGOS), long-chain fructo-oligosaccharides (lcFOS) and pectin-derived acidic oligosaccharides (pAOS) on antibody concentrations after pneumococcal conjugate vaccination in very preterm infants.

Methods: Very preterm infants with gestational age <32 weeks and/or birth weight <1500 g were randomized to receive enteral supplementation with scGOS/lcFOS/pAOS or placebo between days 3 and 30 of life. Blood samples were collected at birth, 5 and 12 months of age and compared with term samples from a Dutch cross-sectional population-based serosurveillance study. IgG antibody levels to pneumococcal capsular polysaccharides were determined by multiplex immunoassay.

Results: In total, 113 preterm infants were included with similar baseline and nutritional characteristics in both groups. After 3 primary pneumococcal vaccinations, the scGOS/lcFOS/pAOS-group had lower GMC antibody concentrations (µg/mL; serotype 4: 1.53, 6B:0.25, 9V: 1.19, 14: 2.39, 18C: 1.88, 19F: 7.42, 23F: 0.72) than the placebo group (serotype 4: 3.29, 6B: 0.79, 9V:2.64, 14: 4.52, 18C: 3.13, 19F: 14.64, 23F: 1.88; all P < 0.05), but comparable with those in the term control group (serotype 4: 0.97, 6B: 0.32, 9V: 1.67, 14: 3.24, 18C: 2.03, 19F: 5.06, 23F: 0.59; all P > 0.05). After the booster vaccination at 11 months, antibody levels were no longer different between the two preterm groups.

Conclusion: Enteral supplementation of scGOS/lcFOS/pAOS has a regulatory effect on the response to conjugated polysaccharide pneumococcal vaccine with normalization of the enhanced responses in preterm infants toward levels similar to healthy term infants.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Antibodies, Bacterial / blood*
  • Cross-Sectional Studies
  • Dietary Supplements*
  • Female
  • Heptavalent Pneumococcal Conjugate Vaccine / administration & dosage*
  • Heptavalent Pneumococcal Conjugate Vaccine / immunology*
  • Humans
  • Immunoassay
  • Immunoglobulin G / blood
  • Infant
  • Infant, Newborn
  • Infant, Premature*
  • Male
  • Oligosaccharides / administration & dosage*
  • Placebos / administration & dosage
  • Treatment Outcome

Substances

  • Antibodies, Bacterial
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Immunoglobulin G
  • Oligosaccharides
  • Placebos

Associated data

  • ISRCTN/ISRCTN16211826